ESTRO 2025 - Abstract Book

S795

Clinical - Gynaecology

ESTRO 2025

space invasion, and cervical involvement to assess whether these factors influenced outcomes between the two treatments.

Results: CRT significantly reduced 5-year pelvic recurrence rates compared to CT alone (1.8% vs. 17.9%; HR 0.09 [0.01–0.71]; P = 0.004), although no significant difference in overall 5-year PFS was observed (67.6% vs. 72.3%; HR 0.75 [0.39– 1.46]; P = 0.393). The major pattern of recurrence was distant metastasis. The 5-year overall rates of distant recurrence were 12.9% in the CT group and 19.3% in the CRT group (hazard ratio [HR] 1.26; 95% confidence interval [CI] 0.56 ‒ 2.89; P = 0.573). Among high-risk patients (stage IIIC, high-grade histology, LVSI, cervical involvement), CRT significantly improved 5 year PFS (62.5% vs. 90.9%; P = 0.049) and pelvic recurrence rates (0% vs. 54.6%; P = 0.008) (Figure 1). For the low- and intermediate-risk groups, the addition of RT to CT provided no added benefit in terms of pelvic recurrence, PFS, or OS. The clinical outcomes by exploratory risk group are detailed in Table 1.